Stryker (NYSE:SYK) Price Target Lowered to $360.00 at Citigroup

Stryker (NYSE:SYK) had its price target reduced by Citigroup from $399.00 to $360.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. Citigroup’s price objective indicates a potential upside of 31.58% from the stock’s previous close.

Several other equities research analysts also recently issued reports on SYK. Royal Bank Of Canada cut their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Raymond James Financial set a $370.00 price target on Stryker in a research report on Friday, July 31st. Leerink Partners decreased their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Argus set a $370.00 price objective on shares of Stryker in a research report on Thursday, July 9th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $317.00 target price on shares of Stryker in a report on Wednesday. Eighteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $380.40.

Stryker Stock Down 0.6%

NYSE SYK traded down $1.79 during trading hours on Thursday, hitting $273.60. 1,164,329 shares of the company traded hands, compared to its average volume of 2,393,981. The stock has a market capitalization of $104.95 billion, a price-to-earnings ratio of 28.38, a P/E/G ratio of 1.73 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker has a twelve month low of $270.85 and a twelve month high of $392.55. The business’s 50-day moving average is $326.77 and its 200-day moving average is $327.62.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker will post 15.03 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares of the company’s stock, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at $2,088,423. This trade represents a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last three months. Insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

Institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System raised its holdings in shares of Stryker by 30,523.4% in the 2nd quarter. California State Teachers Retirement System now owns 163,395,348 shares of the medical technology company’s stock worth $51,443,391,000 after acquiring an additional 162,861,784 shares during the last quarter. State Street Corp boosted its stake in Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after purchasing an additional 311,507 shares during the last quarter. Wellington Management Group LLP increased its holdings in Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Stryker in the fourth quarter worth approximately $1,822,272,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.